According to a new report Asia Pacific Virtual Clinical Trials Market, published by KBV research, the Asia Pacific Virtual Clinical Trials Market would witness market growth of 7.9% CAGR during the forecast period (2020-2026).
The China market dominated the Asia Pacific Virtual Clinical Trials Market by Country in 2019, and would continue to be a dominant market till 2026. The Japan market is experiencing a CAGR of 8.9% during (2020 - 2026). Additionally, The India market is poised to grow at a CAGR of 8.9% during (2020 - 2026).
The Oncology market dominated the South Korea Virtual Clinical Trials Market by Indication in 2019, growing at a CAGR of 6.6 % during the forecast period. The Cardiovascular market is estimated to grow at a CAGR of 6.8% during (2020 - 2026). Additionally, The Immunology market is expected to witness highest CAGR of 9.6% during (2020 - 2026).
The Interventional market dominated the Malaysia Virtual Clinical Trials Market by Study Type in 2019, thereby, achieving a market value of $53.4 million by 2026. The Observational market is witnessing a CAGR of 9.3% during (2020 - 2026). Additionally, The Expanded Access market would showcase highest CAGR of 10.6% during (2020 - 2026).
Structural Insights: https://www.kbvresearch.com/asia-pacific-virtual-clinical-trials-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of IQVIA Holdings, Inc., ICON PLC, Laboratory Corporation of America Holdings (Covance, Inc.), Dassault Systemes SE (Medidata Solutions, Inc.), Oracle Corporation, Parexel International Corporation (Pamplona Capital Management), PRA Health Sciences, Inc. (KKR & Co., Inc.), Medpace Holdings, Inc., Medable, Inc. and Clinical Ink, Inc. (G.I. Partners).
By Study Type
By Indication
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
